Theriva Biologics, Inc. (TOVX)Stock Price & Financial Statements
AboutTheriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.Show more
- Revenue $0
- EBITDA -$26M -23.1%
- Net Income -$26M -39.8%
- EPS (Diluted) -19.03 +33.2%
- Gross Margin -
- EBITDA Margin -
- Operating Margin -
- Net Margin -
- ROE -87.31% -124.3%
- ROIC -142.68% -47.1%
- Debt/Equity 0.08 +51.3%
- Interest Coverage -
Key Insights
Based on financial data analysisStrengths
- ✓Company is almost debt free
- ✓Trading at only 0.0x book value
Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 12 (bottom 12%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-
3Y-
TTM-
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM1.88%
EPS CAGR
10Y-
5Y-
3Y-
TTM83.27%
ROCE
10Y Avg-168.65%
5Y Avg-59.2%
3Y Avg-46.58%
Latest-69.11%
Peer Comparison
Microbiome and Phage Therapeutics| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 ELABPMGC Holdings Inc. | 23.88K | 1.05 | -0.00 | 44.07% | -253.14% | -78.44% | ||
TOVXTheriva Biologics, Inc. | 252.1K | 0.19 | -0.01 | -388.69% | 0.08 | |||
 AZTRAzitra, Inc. | 2.03M | 0.19 | -0.08 | -100% | -0.29% | 0.11 | ||
 EVGNEvogene Ltd. | 7.31M | 0.84 | -0.29 | 50.9% | -52.33% | -15.93% | 0.87 | |
 SYBXSynlogic, Inc. | 7.02M | 0.60 | -0.31 | -99.76% | -2919.88% | -31.25% | ||
 MCRBSeres Therapeutics, Inc. | 80.02M | 9.13 | -0.48 | 15.37% | 12.34% | 6.65 | ||
 PHGEBiomX Inc. | 82.77B | 6.30 | -4.29 | -356.43% | 0.40 | |||
 ARMPArmata Pharmaceuticals, Inc. | 419.83M | 11.61 | -22.19 | 14.24% | -9.28% |
Compare TOVX vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 72K | 157K | 245K | 272K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -72K | -157K | -245K | -272K | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -118.06% | -56.05% | -11.02% | 100% | - | - | - | - | - |
| Operating Expenses | 40.98M | 39.25M | 26.25M | 17.57M | 15.66M | 10.16M | 14.27M | 21.58M | 21.43M | 26.35M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 8.07M | 10.14M | 7.47M | 5.73M | 4.58M | 5.03M | 6.47M | 7.57M | 7.78M | 7.4M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 32.91M | 29.11M | 18.78M | 11.84M | 11.08M | 5.13M | 7.8M | 11.72M | 14.31M | 12.03M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.29M | -660K | 6.92M |
| Operating Income | -40.98M | -39.25M | -26.25M | -17.57M | -15.66M | -10.16M | -14.27M | -21.58M | -21.43M | -26.35M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -99.88% | 4.22% | 33.12% | 33.07% | 10.86% | 35.13% | -40.49% | -51.19% | 0.7% | -22.93% |
| EBITDA | -40.91M | -39.09M | -26.01M | -17.3M | -15.42M | -9.96M | -14.19M | -21.5M | -21.3M | -26.21M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -99.73% | 4.43% | 33.48% | 33.48% | 10.84% | 35.43% | -42.45% | -51.52% | 0.93% | -23.07% |
| D&A (Non-Cash Add-back) | 72K | 157K | 245K | 272K | 240K | 201K | 87K | 85K | 135K | 137K |
| EBIT | -40.98M | -39.25M | -26.25M | -17.57M | -15.66M | -10.16M | -14.27M | -19.29M | -22.09M | -19.43M |
| Net Interest Income | 0 | 0 | 0 | 0 | 283K | 44K | 6K | 512K | 1.44M | 697K |
| Interest Income | 6K | 37K | 21K | 67K | 283K | 44K | 6K | 512K | 1.44M | 697K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -3.81M | 11.45M | 10.76M | 4.15M | 283K | 44K | 6K | 471K | 1.44M | 693K |
| Pretax Income | -44.78M | -27.8M | -15.49M | -13.42M | -15.38M | -10.12M | -14.27M | -21.11M | -19.99M | -25.65M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.43M | -1.64M | 0 |
| Effective Tax Rate % | 97.66% | 98.03% | 97.95% | 99.6% | 99.5% | 99.28% | 99.99% | 93.25% | 91.8% | 100% |
| Net Income | -43.74M | -27.25M | -15.17M | -13.37M | -15.3M | -10.04M | -14.27M | -19.68M | -18.35M | -25.65M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -121.07% | 37.68% | 44.33% | 11.91% | -14.48% | 34.37% | -42.06% | -37.98% | 6.79% | -39.81% |
| Net Income (Continuing) | -44.78M | -27.8M | -15.49M | -13.42M | -15.38M | -10.12M | -14.27M | -19.68M | -18.35M | -25.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -1.05M | -1.6M | -1.91M | -2.91M | -2.88M | -2.77M | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -189.68 | -101.17 | -42.70 | -21.45 | -9.14 | -6.60 | -1.90 | -32.66 | -28.48 | -19.03 |
| EPS Growth % | -69.69% | 46.66% | 57.79% | 49.77% | 57.39% | 27.79% | 71.21% | -1618.95% | 12.8% | 33.18% |
| EPS (Basic) | -189.68 | -101.17 | -42.70 | -21.45 | -9.14 | -6.60 | -1.90 | -32.66 | -28.49 | -19.03 |
| Diluted Shares Outstanding | 230.58K | 269.4K | 355.33K | 623.24K | 1.64M | 1.9M | 12.19M | 613.09K | 644.28K | 1.35M |
| Basic Shares Outstanding | 230.58K | 269.4K | 355.33K | 623.24K | 1.64M | 1.9M | 12.19M | 613.09K | 644K | 1.35M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 30.34M | 21.57M | 17.94M | 29.51M | 16.43M | 7.93M | 68.86M | 45.52M | 27.4M | 16.28M |
| Cash & Short-Term Investments | 20.82M | 19.05M | 17.12M | 28.92M | 15.04M | 6.23M | 67.33M | 41.79M | 23.18M | 11.61M |
| Cash Only | 20.82M | 19.05M | 17.12M | 28.92M | 15.04M | 6.23M | 67.33M | 41.79M | 23.18M | 11.61M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 185K | 46K | 0 | 3K | 469K | 0 | 231K | 1.94M | 3.32M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 8.97M | 1.68M | 0 | 0 | 0 | 0 | 458K | 0 | 0 | 0 |
| Total Non-Current Assets | 508K | 928K | 895K | 630K | 809K | 476K | 1.51M | 26.34M | 27.82M | 19.07M |
| Property, Plant & Equipment | 494K | 905K | 872K | 607K | 786K | 453K | 1.48M | 1.54M | 2.18M | 1.54M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.53M | 5.7M | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.15M | 19.75M | 17.36M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 99K | 102K | 0 |
| Other Non-Current Assets | 14K | 23K | 23K | 23K | 23K | 23K | 23K | -3.15M | 78K | 171K |
| Total Assets | 30.84M | 22.5M | 18.84M | 30.14M | 17.23M | 8.41M | 70.36M | 71.86M | 55.22M | 35.35M |
| Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 61.12% | -27.06% | -16.27% | 60% | -42.82% | -51.2% | 736.68% | 2.13% | -23.16% | -35.98% |
| Total Current Liabilities | 15.57M | 19.76M | 9.79M | 3.38M | 5.28M | 2.97M | 3.55M | 7.06M | 6.74M | 7.58M |
| Accounts Payable | 4.41M | 1.99M | 2.02M | 1.03M | 2.31M | 886K | 524K | 915K | 770K | 859K |
| Days Payables Outstanding | 22.37K | 4.63K | 3.01K | 1.39K | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 57K | 63K | 61K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 10.59M | 14.82M | 4.17M | 99K | 0 | 868K | 0 | 4.47M | 906K | 1.8M |
| Current Ratio | 1.95x | 1.09x | 1.83x | 8.72x | 3.11x | 2.67x | 19.37x | 6.45x | 4.07x | 2.15x |
| Quick Ratio | 1.95x | 1.09x | 1.83x | 8.72x | 3.11x | 2.67x | 19.37x | 6.45x | 4.07x | 2.15x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 267K | 492K | 12.46M | 302K | 473K | 186K | 1.4M | 10.24M | 8.78M | 8.7M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 221K | 162K | 92K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 473K | 186K | 1.4M | 1.19M | 1.44M | 873K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.62M | 0 | 762K |
| Other Non-Current Liabilities | 267K | 492K | 402K | 302K | 0 | 0 | 0 | 7.21M | 7.18M | 6.97M |
| Total Liabilities | 15.84M | 20.25M | 22.25M | 3.69M | 5.75M | 3.15M | 4.96M | 17.3M | 15.52M | 16.29M |
| Total Debt | 0 | 0 | 0 | 0 | 722K | 473K | 1.53M | 1.68M | 2.15M | 1.56M |
| Net Debt | -20.82M | -19.05M | -17.12M | -28.92M | -14.32M | -5.75M | -65.8M | -40.1M | -21.02M | -10.04M |
| Debt / Equity | - | - | - | - | 0.06x | 0.09x | 0.02x | 0.03x | 0.05x | 0.08x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 15M | 2.25M | -3.41M | 26.45M | 11.49M | 5.26M | 65.41M | 54.56M | 39.7M | 19.07M |
| Equity Growth % | 57% | -85.01% | -251.62% | 875.81% | -56.58% | -54.23% | 1143.97% | -16.58% | -27.25% | -51.97% |
| Book Value per Share | 65.07 | 8.35 | -9.60 | 42.45 | 6.99 | 2.77 | 5.37 | 89.00 | 61.61 | 14.14 |
| Total Shareholders' Equity | 16.05M | 3.85M | -1.5M | 29.36M | 14.37M | 8.03M | 65.41M | 54.56M | 39.7M | 19.07M |
| Common Stock | 91K | 117K | 129K | 15K | 17K | 29K | 13K | 16K | 18K | 3K |
| Retained Earnings | -144.78M | -172.03M | -194.17M | -219.46M | -235.54M | -248.09M | -271.28M | -290.97M | -309.32M | -334.97M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -288K | -288K | -288K |
| Accumulated OCI | 0 | 0 | -12.05M | 0 | 0 | 0 | 0 | -679K | 32K | -1.18M |
| Minority Interest | -1.05M | -1.6M | -1.91M | -2.91M | -2.88M | -2.77M | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -38.89M | -27.9M | -20.2M | -17.28M | -13.87M | -12.17M | -12.89M | -19.08M | -19M | -16.94M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -141.87% | 28.26% | 27.59% | 14.48% | 19.71% | 12.29% | -5.93% | -48.04% | 0.45% | 10.84% |
| Net Income | -44.78M | -27.8M | -15.49M | -13.42M | -15.38M | -10.12M | -14.27M | -19.68M | -18.35M | -25.65M |
| Depreciation & Amortization | 72K | 157K | 245K | 272K | 240K | 201K | 87K | 85K | 135K | 137K |
| Stock-Based Compensation | 3.2M | 4.01M | 3.41M | 2.07M | 340K | 350K | 416K | 475K | 552K | 671K |
| Deferred Taxes | 0 | 0 | 0 | -4.08M | 0 | 0 | 0 | -1.43M | -1.64M | -888K |
| Other Non-Cash Items | 8.16M | -11.41M | -10.74M | 71K | 72K | 178K | 166K | 2.27M | -2M | 8.07M |
| Working Capital Changes | -5.54M | 7.15M | 2.37M | -2.19M | 855K | -2.78M | 709K | -806K | 2.31M | 726K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 3.42M | -2.42M | 27K | -987K | 1.28M | -1.43M | -363K | -385K | -157K | 123K |
| Cash from Investing | -501K | -569K | -212K | -7K | 0 | -9K | -14K | -4.4M | -202K | -1K |
| Capital Expenditures | -501K | -569K | -212K | -7K | 0 | -9K | -14K | -116K | -202K | -1K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.28M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.28K | 0 | 0 |
| Cash from Financing | 42.68M | 26.71M | 18.48M | 29.09M | 0 | 3.36M | 74M | -1.93M | 625K | 5.5M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.38M | -75K | -67K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -288K | 0 | 0 |
| Other Financing | -3.32M | 198K | 166K | 0 | 0 | 0 | 8.04M | -3M | -1.52M | 0 |
| Net Change in Cash | 3.29M | -1.76M | -1.94M | 11.8M | -13.87M | -8.82M | 61.1M | -25.44M | -18.61M | -11.57M |
| Free Cash Flow | -39.39M | -28.47M | -20.42M | -17.29M | -13.87M | -12.18M | -12.9M | -19.2M | -19.2M | -16.94M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -144.25% | 27.72% | 28.29% | 15.33% | 19.74% | 12.23% | -5.97% | -48.78% | 0% | 11.77% |
| FCF per Share | -170.83 | -105.68 | -57.46 | -27.74 | -8.44 | -6.41 | -1.06 | -31.31 | -29.80 | -12.56 |
| FCF Conversion (FCF/Net Income) | 0.89x | 1.02x | 1.33x | 1.29x | 0.91x | 1.21x | 0.90x | 0.97x | 1.04x | 0.66x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Key Ratios
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -356.18% | -315.96% | - | -116.01% | -80.67% | -119.95% | -40.38% | -32.82% | -38.93% | -87.31% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | -230.09% | -97.02% | -142.68% |
| Debt / Equity | - | - | - | - | 0.06x | 0.09x | 0.02x | 0.03x | 0.05x | 0.08x |
| FCF Conversion | 0.89x | 1.02x | 1.33x | 1.29x | 0.91x | 1.21x | 0.90x | 0.97x | 1.04x | 0.66x |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics